PFS with ibrutinib in patients with relapsed/refractory CLL by chromosomal abnormalities detected by fluorescence in situ hybridization (A), by presence or absence of del(17p) among those with complex karyotype (CK) (B), and by IGHV mutational status (C). See complete Figures 3, 4, and 6 in the article by O’Brien et al that begins on page 1910.